Related Experiment Video
Updated: Oct 16, 2025
A Novel Method to Determine the Longitudinal Antibacterial Activity of Drug-Eluting Materials
Published on: March 3, 2023
Antibacterial Activity of LCB10-0200 against Klebsiella pneumoniae
Sang-Hun Oh1, Young-Rok Kim1, Hee-Soo Park2
1School of Life Science, Handong Global University, Pohang 37554, Korea.
Abstract:
Klebsiella pneumoniae is one of the important clinical organisms that causes various infectious diseases, including urinary tract infections, necrotizing pneumonia, and surgical wound infections. The increase in the incidence of multidrug-resistance K. pneumoniae is a major problem in public healthcare. Therefore, a novel antibacterial agent is needed to treat this pathogen. Here, we studied the in vitro and in vivo activities of a novel antibiotic LCB10-0200, a siderophore-conjugated cephalosporin, against clinical isolates of K. pneumoniae. In vitro susceptibility study found that LCB10-0200 showed potent antibacterial activity against K. pneumoniae, including the beta-lactamase producing strains. The in vivo efficacy of LCB10-0200 was examined in three different mouse infection models, including systemic, thigh, and urinary tract infections. LCB10-0200 showed more potent in vivo activity than ceftazidime in the three in vivo models against the drug-susceptible and drug-resistant K. pneumoniae strains. Taken together, these results show that LCB10-0200 is a potential antibacterial agent to treat infection caused by K. pneumoniae.
Insights
A new antibiotic, LCB10-0200, shows strong antibacterial effects against multidrug-resistant Klebsiella pneumoniae. This novel cephalosporin is effective both in vitro and in vivo, offering a promising treatment for K. pneumoniae infections.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Klebsiella pneumoniae is a significant clinical pathogen causing severe infections.
- Rising multidrug-resistance in K. pneumoniae poses a major public health threat.
- Novel therapeutic strategies are urgently required to combat K. pneumoniae infections.
Purpose of the Study:
- To evaluate the in vitro and in vivo efficacy of LCB10-0200 against Klebsiella pneumoniae.
- To assess LCB10-0200 as a potential treatment for K. pneumoniae infections, including drug-resistant strains.
Main Methods:
- In vitro susceptibility testing of LCB10-0200 against clinical isolates of K. pneumoniae.
- In vivo efficacy assessment in mouse models of systemic, thigh, and urinary tract infections.
- Comparative analysis of LCB10-0200 and ceftazidime in established infection models.
Main Results:
- LCB10-0200 demonstrated potent in vitro antibacterial activity against K. pneumoniae, including beta-lactamase producing strains.
- LCB10-0200 exhibited superior in vivo efficacy compared to ceftazidime in systemic, thigh, and urinary tract infection models.
- The antibiotic was effective against both drug-susceptible and drug-resistant K. pneumoniae strains in vivo.
Conclusions:
- LCB10-0200 is a potent novel antibiotic with significant antibacterial activity against Klebsiella pneumoniae.
- The siderophore-conjugated cephalosporin LCB10-0200 shows promise as a therapeutic agent for K. pneumoniae infections.
- Further development of LCB10-0200 could provide a valuable option for treating infections caused by multidrug-resistant K. pneumoniae.
More Related Videos
09:26Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung
Published on: January 22, 2021
06:05Using the Overlay Assay to Qualitatively Measure Bacterial Production of and Sensitivity to Pneumococcal Bacteriocins
Published on: September 30, 2014
